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To select the most useful evaluative outcome measures for early multiple sclerosis, we included 156 recently
diagnosed patients in a 3-year follow-up study, and assessed them on 23 outcome measures in the domains of
disease-specific outcomes, physical functioning, mental health, social functioning and general health. A global
rating scale (GRS) and the Expanded Disability Status Scale (EDSS) were used as external criteria to determine
the minimally important change (MIC) for each outcomemeasure. Subsequently, we determined whether the
outcome measures could detect their MIC reliably. From these, per domain the outcome measure that was
found to bemost sensitive to changes (responsive) was identified. At group level, 11 outcomes of the domains of
physical functioning,mental health, social functioning and general health could reliably detect theMIC. Of these
11, the most responsive measures per domain were the Medical Outcome Study 36 Short Form sub-scale
physical functioning (SF36pf), the Disability and Impact Profile (DIP) sub-scale psychological, the Rehabilitation
Activities Profile sub-scale occupation (RAPocc) and the SF36 sub-scale health, respectively. Overall, the most
responsive measures were the SF36pf and the RAPocc. In individual patients, none of the measures could
reliably detect the MIC. In sum, in the early stages of multiple sclerosis the most useful evaluative outcome
measures for research are the SF36pf (physical functioning) and the RAPocc (social functioning).
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Introduction
The Expanded Disability Status Scale (EDSS) is a frequently
used and well-known outcome measure for multiple
sclerosis. However, it is criticized because it has unsatisfac-
tory validity, and its reliability is poor (Noseworthy, 1994;
Sharrack and Hughes, 1999; Hobart et al., 2000). In response
to this situation, the National Multiple Sclerosis Society
Clinical Outcomes Assessment Task Force reviewed a large
number of data sets to determine which outcome measures
would adequately reflect the consequences of the disease
and are capable of reliably assessing these consequences.
(Cutter et al., 1999; Fischer et al., 1999). This led to the
development of the Multiple Sclerosis Functional Composite
Measure (MSFC), which consists of the 25-foot timed-walk
test (TWT), the nine-hole peg test (NHPT) and the paced
auditory serial addition test (PASAT). Originally, the Task
Force intended to include a measure of visual acuity, but no
reliable measure could be found. The MSFC is intended to
replace the EDSS as outcome measure in current and future
trials (Cutter et al., 1999; Miller et al., 2000; Cohen et al.,
2001). The interpretation of the scores of the individual
components of the MSFC is straightforward. However, the
total score, which results from a relatively complex formula
to combine the component scores, is more difficult to
interpret. An adaptation of the MSFC, the short and graphic
assessment scale (SaGAS), (Vaney et al., 2004) uses only
the TWT and the NHPT. Through specific transformation,
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a score is obtained that should be easier to interpret. Other
newly developed disease-specific outcomes are the multiple
sclerosis impact scale (Hobart et al., 2001a) and the Guy’s
Neurological Disability Scale (Sharrack and Hughes, 1999).
In addition to these new, disease-specific, measures, several
other disability and quality of life measures have been
used in research into this illness (Granger et al., 1990; Kidd
et al., 1995; Jonsson et al., 1996; Lankhorst et al., 1996;
Ottenbacher et al., 1996; Cohen et al., 1999; Pfennings et al.,
1999a; Van der Putten et al., 1999; Freeman et al., 2000;
Hobart et al., 2001b).
Responsiveness is an important clinimetric property. It
represents the ability to measure change, and is particularly
relevant when outcome measures are to be used in long-
itudinal studies, such as clinical trials (De Vet et al., 2001;
Terwee et al., 2003). In connection with multiple sclerosis,
however, it has been studied much less extensively than
validity and reliability (Koziol et al., 1999; Sharrack and
Hughes, 1999; Schwid et al., 2000; Hoogervorst et al., 2001a;
Patzold et al., 2002; Uitdehaag et al., 2002; Riazi et al., 2003;
Hobart et al., 2004; McGuigan and Hutchinson, 2004).
Moreover, in the literature there is no consensus about the
exact definition of responsiveness (Terwee et al., 2003).
Consequently, there are many currently available methods
that have been developed to assess responsiveness (Terwee
et al., 2003; Crosby et al., 2003; Husted et al., 2000). It has
been shown that applying different methods leads to
different conclusions about the absolute responsiveness
of an outcome measure (Terwee et al., 2003). However,
conclusions about the relative responsiveness, i.e. how do
different measures perform in relation to each other, are
less dependent on the method used (Terwee et al., 2003). To
assess the relative responsiveness, several outcome measures
of interest should be included, and parallel assessments
should be made at the same points in time.
The methods that can be used to assess whether scores
have changed can be sub-divided into distribution-
based and anchor-based methods (Lydick and Epstein,
1993; Cella et al., 2002a, b; Schmitt and Di Fabio, 2004)
Distribution-based methods, using standardized metrics,
focus on the ability of an outcome measure to reliably
determine change, and aim to quantify the noise, i.e. the
variability of the score changes in the absence of a relevant
change. Anchor-based methods focus on the correspondence
of the change on the outcome measure of interest with
the change on an external criterion (Cella et al., 2002a;
Schunemann et al., 2003) and aim to quantify the signal,
i.e. the size of the score change when there is a relevant
change. The results of anchor-based methods depend on the
external criterion and the cut-off point chosen (Cella et al.,
2002a). The usefulness of an evaluative outcome measure
depends on whether score changes associated with a relevant
change can reliably be distinguished from the variability of
score changes in absence of a relevant change (Guyatt et al.,
1987).
In this study, 23 (sub-scales of) outcome measures were
compared. The aim was to select the most useful evaluative
outcome measures for the early stages of multiple sclerosis.
Material and methods
Patients
All consecutive potentially eligible patients visiting the participating
neurology outpatient clinics were invited to participate. A cohort
of 156 recently (<6 months previously) diagnosed patients, aged
16–55 years, was recruited and followed prospectively for 3 years.
Diagnosis was based on the Poser criteria for definite multiple
sclerosis (Poser et al., 1983) Patients with other neurological dis-
orders, or systemic or malignant neoplastic diseases, were excluded.
The measurements took place at baseline, and 6 months, and after
1, 2 and 3 years. In the case of a relapse, the measurements were
postponed for a few weeks until the relapse had subsided. The
patients were visited at home in order to minimize drop-out. Four
well-trained raters were responsible for the scoring.
Outcome measures
We studied the (sub-)scales of the EDSS (Kurtzke, 1983; Whitaker
et al., 1995; Rudick et al., 1996), the MSFC (Cutter et al., 1999;
Fischer et al., 1999; Cohen et al., 2000; Kalkers et al., 2000, 2001;
Miller et al., 2000; Hoogervorst et al., 2001b), the SaGAS (Vaney
et al., 2004), the Action Research Arm Test (ARAT) (Lyle, 1981;
Van der Lee et al., 2001), the Disability and Impact Profile (DIP)
(Laman and Lankhorst, 1994; Jonsson et al., 1996; Lankhorst et al.,
1996; Cohen et al., 1999; Pfennings et al., 1999a), the Functional
Independence Measure (FIM) (Granger et al., 1990; Kidd et al.,
1995; Marolf et al., 1996), the Rehabilitation Activities Profile
(RAP) (Van Bennekom et al., 1995, 1996), the Rivermead Mobility
Index (RMI) (Collen et al., 1991; Forlander and Bohannon, 1999;
Hsieh et al., 2000; Antonucci et al., 2002) and the Medical Outcome
Study Short Form 36 (SF36). (Vickrey et al., 1995; Brunet et al.,
1996; Freeman et al., 2000; Hobart et al., 2001b). The 23 (sub-
)scales covered 5 domains: 3 disease-specific measures, 10
physical functioning measures (5 mobility measures, 3 self-care
measures and 2 upper limb function measures), 4 mental health
measures (2 cognitive function measures and 2 emotional well-
being measures), 5 social functioning measures and 1 general health
measure. Of these, 11 outcome measures were questionnaires,
7 were (parts of) measures that required physical examination or
testing procedures and 5 outcome measures were based on semi-
structured interviews. When possible, outcome measures were
transformed into a scale ranging from 100 (best) to 0 (worst).
Scores on the NHPT, the 10-m TWT, the MSFC, and the SaGAS
could not be transformed in this way, because these continuous
scales do not have defined end-points for best or worst scores.
Table 1 presents an overview of the outcome measures and the
baseline scores (standard deviation).
Analysis of responsiveness
To determine whether a patient’s score had changed, we applied
two external criteria: (i) a 7-point Likert-type patient rated global
rating scale (GRS) of change, using the situation at diagnosis as
reference point, (Jaeschke et al., 1989; Juniper et al., 1994; Liang,
1995; Stucki et al., 1995; Bessette et al., 1998; Cella et al., 2002b;
Guyatt et al., 2002) emphasizing the perspective of the patient, and
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(ii) a change on the EDSS, representing the perspective of the
clinician. The GRS question asked was: ‘How would you rate your
current health when compared with your health at the time of
diagnosis?’ The answering categories were: very much improved,
much improved, slightly improved, stable, slightly deteriorated,
much deteriorated, and very much deteriorated. The EDSS is a
single-scale measure that ranges from 0 = a normal neurological
examination, to 10 = death due to multiple sclerosis.
To assess the relative responsiveness, that is relatively
independent of the method used to assess the responsiveness,
(Terwee et al., 2003) we calculated the area under the receiver
operating characteristic (ROC) curve with its 95% confidence
interval (AUC, 95% CI) for every outcome measure, using score
changes since baseline at 3 years (Beurskens et al., 1996; Van der
Windt et al., 1998; De Vet et al., 2001; Mancuso and Peterson,
2004). We used a non-parametric method which does not make any
assumptions about the distributions to compute the AUC. Figure 1
shows an example of twoROCcurves. The relative responsiveness was
assessed separately for deterioration and improvement. For both
external criteria the scores were dichotomized, using the category
stable (no change) as reference category.
The minimally important change score of an outcome measure
(MIC) is calculated as the mean change score in patients who
showed a minimally important change according to an external
criterion (Wyrwich et al., 1999). For the GRS of the patient’s
perspective we used the categories of slightly improved or slightly
deteriorated to identify the patients who showed a minimally
Fig. 1 ROC curves. In a ROC curve the sensitivity is plotted
against 1–specificity. The AUC is a measure of the responsiveness
of the outcome measure. An AUC <0.5 (diagonal line) indicates
that the outcome measure is not responsive. The more the ROC
curve approaches the upper left corner the more responsive the
outcome measure is.
Table 1 Outcome measures studied and baseline scores of 156 multiple sclerosis patients
Outcome measure Sub-scale Type Transformed baseline score
[0–100% (SD)]
Disease-specific
EDSS Expanded Disability Status Scale pt 74.9 (11.2)
MSFC Multiple Sclerosis Functional Composite pt 0.0 (0.7)*
SaGAS Short and Graphic Assessment Scale pt 7.0 (0.4)*
Physical functioning
Mobility
DIPmob Disability and Impact Profile Mobility q 86.9 (10.5)
RAPmob Rehabilitation Activities Profile Mobility i 85.7 (14.1)
RMI Rivermead Mobility Index q 95.7 (8.7)
SF36pf Medical Outcome Study Short Form 36 Physical functioning q 71.3 (23.5)
TWT 10-m timed-walk test pt 6.4 (3.2) s*
Self-care
DIPself Disability and Impact Profile Self-care q 94.3 (8.6)
FIMmf Functional Independence Measure Motor function i 95.2 (5.4)
RAPself Rehabilitation Activities Profile Self-care i 92.3 (11.1)
Upper limb function
ARAT Action Research Arm Test pt 99.1 (4.0)
NHPT Nine-hole peg test pt 21.1 (4.0) s*
Mental health
Cognitive function
FIMcf Functional Independence Measure Cognitive function i 95.2 (5.2)
PASAT3 Paced serial addition test 3-second version pt 76.9 (18.3)*
Emotional well-being
DIPpsy Disability and Impact Profile Psychological q 79.4 (12.3)
SF36mh Medical Outcome Study Short Form 36 Mental health q 72.1 (17.5)
Social functioning
DIPsoc Disability and Impact Profile Social functioning q 87.0 (10.2)
RAPocc Rehabilitation Activities Profile Occupation i 75.0 (20.6)
SF36re Medical Outcome Study Short Form 36 Role emotional q 74.1 (37.0)
SF36rp Medical Outcome Study Short Form 36 Role physical q 51.9 (42.0)
SF36sf Medical Outcome Study Short Form 36 Social functioning q 77.9 (23.2)
General health
SF36gh Medical Outcome Study Short Form 36 General Health q 52.6 (19.8)
pt = performance test; q = questionnaire; i = interview by professional.
*Not transformed into a 100 (best) to 0 (worst) scale.
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important change. Figure 2 illustrates graphically were the MIC is
located on the spectrum of change-scores. The next possible
categories, namely much improved or much deteriorated, were not
used, because they indicate substantial improvement or deteriora-
tion. For EDSS of the clinician’s perspective we used an
improvement or deterioration of one point since baseline, because
a change of one EDSS point is frequently used in trials and is the
lowest EDSS change that can reliably be detected in the lower EDSS
ranges (Noseworthy et al., 1990; Goodkin et al., 1992). TheMIC was
calculated from the patient’s perspective (MIC-Pimprovement andMIC-
Pdeterioration), and the clinician’s perspective (MIC-Cimprovement and
MIC-Cdeterioration). Because the longitudinal study design had five
repeated measurements, we used generalized estimating equations
(GEE) to estimate the MIC. This regression analysis technique
for longitudinal data makes optimal use of the available data
and reduces the standard error of the estimates, while at the same time
correcting for the dependence between subsequent measurements
(Zeger and Liang, 1986) The correlation structure was chosen on the
basis of the correlation matrix of the outcome measures, and set at
exchangeable (i.e. correlation coefficients between the first and
successive measurements are approximately equal) for all outcomes
except the cognitive sub-scale of the FIM that was set at 4-dependence
(i.e. correlation coefficients between the first and successive
measurements are progressively smaller). Scores on the outcome
measureswere used as dependent variable [Y(t)], and time (t, in years)
and four dummy variables based on the external criteria (deterio-
rated, slightly deteriorated, slightly improved, improved) were used
as independent variables. The stable group was used as reference.
Because theGRSused the time of diagnosis as reference point, we used
an autoregression formula that also includes the score for the
outcome measure at baseline [Y(t0)] as independent variable. In the
formula:
YðtÞ ¼ aþ b1 * Yðt0Þ þ b2 · t þ b3 · deteriorated
þ b4 · slightly deterioratedþ b5 · slightly improved
þ b6 · improved
b4 is interpreted as the mean score change on the outcome measure
for patients who were slightly deteriorated, and provides an estimate
for the MICdeterioration. b5 is interpreted as the mean score change on
the outcome measure for patients who were slightly improved, and
provides an estimate for the MICimprovement.
To assess the reliability of two scores on each outcome measure,
we used the smallest real change (SRC) (Pfennings et al., 1999b;
Beckerman et al., 2001; De Vet et al., 2001). The SRC is more often
referred to as the smallest real difference, but since our main focus
Fig. 2 Relationship between SRC and MIC. (A) Shows the distribution of change scores for the categories (stable, slightly deteriorated and
deteriorated) of the external criterion. There is minimal overlap between scores and the MIC is much larger than the SRC. This outcome
measure is useful. (B) Shows again the distribution of change-scores for each category of the external criterion. There is much overlap
between the scores and the MIC is smaller than the SRC. This outcome measure is not useful.
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is on intra-individual changes, we prefer to use the term smallest
real change. For each external criterion the SRC was calculated in
the sub-group of patients who did not change, according to the
external criterion during the first 6 months after inclusion. The
SRC takes two sources of variability into account: (i) the reliability
of the outcome measure, and (ii) the naturally occurring variability
in stable patients. The SRC offers the opportunity to calculate
a measure for comparisons at group level (SRCgroup) and at
individual level (SRCindividual) (Pfennings et al., 1999b). The
SRCindividual was calculated as 1.96 · SD of the score changes in
stable patients. Figure 2 shows graphically where the SRC is located
on the spectrum of change-scores. The SRCgroup was calculated as
SRCindividual /Hn.
The selection of the most useful evaluative outcome measure
was based on the relative responsiveness (highest AUC), whether
the MIC > SRCindividual or SRCgroup, (see Fig. 2) and whether
the results were comparable for both external criteria. For each
outcome measure we calculated the sample sizes (patients per
group) needed to show differences between independent samples in
future studies. We used the formula 2 · {[(Za + Zb) · (SRCgroup/
1.96)]/MIC}2 (Guyatt et al., 1987), where a is set at 0.05 (Za = 1.96)
and b is set at 0.20 (Zb = 0.84), in order to achieve a power of 0.80.
The statistical analyses were performed with SPSS version 11.5
for Windows. GEE analyses were performed with the Statistical
Package for Interactive Data Analysis (SPIDA) version 6.05 from
the Statistical Computing Laboratory.
Results
A total of 156 patients were included in the cohort between
January 1998 and January 2001. Table 2 shows the baseline
characteristics of these patients. Most characteristics comply
with the expected pattern: more females than males in the
relapsing–remitting group, more males than females in the
primary progressive group, and more severe neurological
deficits in the primary progressive group. Seven patients
were lost to follow-up (three after 1 year, one after 2 years
and three after 3 years), and 15 measurements were missing.
The baseline scores on the outcome measure are presented
in Table 1.
Table 3 shows the distribution of GRS and EDSS scores
for each measurement. The distributions are remarkably
different. The GRS scores are more equally spread across the
categories, and according to the GRS fewer patients were
stable, and more patients had improved. Over time there is a
tendency for both external criteria to change towards
deterioration. The percentage of patients that deteriorated
(taking categories deteriorated and slightly deteriorated
together) according to the patient’s and clinician’s
perspective, respectively, is 36 and 22% at 6 months, 46
and 33% at 1, 50 and 46% at 2, and 60 and 44% at 3 years.
The agreement between the patient’s and clinician’s
perspective to classify patients as deteriorated, stable or
improved is 35% (k = 0.10) at 6 months, 42% (k = 0.14) at
1, 40% (k = 0.07) at 2, and 45% (k = 0.13) at 3 years.
Tables 4 and 5 show that the AUCs range from 0.50 to
0.75 and have wide CIs. For five (patient’s perspective) and
seven (clinician’s perspective) outcome measures the AUC
does not significantly differ from 0.50. For a substantial
number of outcome measures the MIC does not significantly
differ from zero, which means that the MIC cannot be
Table 3 Distribution (n, %) of the GRS (patient’s perspective) and EDSS (clinician’s perspective) based external criteria for
each measurement
External criteria Patient’s perspective (%) Clinician’s perspective (%)
6 months 1 year 2 years 3 years 6 months 1 year 2 years 3 years
(n = 113) (n = 130) (n = 141) (n = 145) (n = 153) (n = 47) (n = 145) (n = 146)
Deteriorated 11 (10) 15 (12) 19 (13) 28 (19) 12 (8) 24 (16) 40 (28) 41 (28)
Slightly deteriorated 29 (26) 44 (34) 52 (37) 60 (41) 21 (14) 25 (17) 26 (18) 24 (16)
Stable 26 (23) 30 (23) 29 (21) 22 (15) 100 (65) 79 (54) 66 (46) 69 (47)
Slightly improved 14 (12) 11 (8) 19 (13) 10 (7) 11 (7) 11 (7) 11 (8) 8 (5)
Improved 33 (29) 30 (23) 22 (16) 25 (17) 9 (6) 8 (5) 2 (1) 4 (3)
For deterioration and improvement the categories were ‘very much’ and ‘much’ have been combined.
Table 2 Baseline characteristics of patients with multiple sclerosis
Characteristics RR SP PP Not yet known Total
n (%) 120 (77) 8 (5) 25 (16) 3 (2) 156 (100)
Age (SD) 35.5 (8.9) 48.2 (6.7) 43.2 (8.9) 45.5 (6.9) 37.6 (9.5)
Gender
Female (%) 84 (70.0) 3 (37.5) 11 (44) 3 (100) 101 (64)
Time since diagnosis (years) 0.26 (0.15–0.41) 0.33 (0.24–0.48) 0.28 (0.15–0.33) 0.14 (0.14–0.17) 0.26 (0.15–0.40)
Time since symptoms (years) 1.83 (0.67–4.40) 7.50 (3.35–14.51) 2.10 (1.07–3.15) 3.62 (3.53–4.63) 2.15 (0.79–4.36)
Number of exacerbations 2.0 (1.0–3.0) 2.0 (1.0–7.0) 0 (0–0) 0 (0–0) 2.0 (1.0–3.0)
EDSS 2.0 (2.0–3.0) 3.0 (2.5–3.9) 3.0 (2.5–4.0) 2.5 (2.0–4.0) 2.5 (2.0–3.0)
n (percentage), mean (SD) or median (IQR). RR = relapsing–remitting multiple sclerosis; SP = secondary progressive multiple sclerosis;
PP = primary progressive multiple sclerosis. EDSS, original score.
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detected beyond chance for these outcome measures in this
population. It also means that these outcome measures
are not suitable to evaluate change in this population.
Furthermore, none of the outcome measures has an MIC >
SRCindividual, which makes the outcome measures unsuitable
to detect an minimally important change in an individual
patient. However, several measures have an MIC > SRCgroup,
which makes them suitable for research purposes. The final
columns in the tables show a large variation in required
sample sizes. The unrealistically high estimates of the sample
sizes are caused by large estimates of the SRCindividual relative
to the estimate of the MIC.
The results for deterioration from the patient’s perspective
can be found in Table 4. Of the disease-specific outcome
measures, the EDSS has the highest AUC [0.70 (95% CI
0.62–0.79)]. For all three disease-specific outcome measures
the MIC-Pdeterioration is small, and does not significantly
differ from zero. Of the outcome measures related to
physical functioning, the SF36pf has the highest AUC
[0.75 (95% CI 0.67–0.84)] and an MIC-Pdeterioration (8.58)
that exceeds the SRCgroup (4.38). Of the outcome measures
related to mental health, the FIM sub-scale cognitive
function (FIMcf) and the DIP sub-scale psychological
(DIPpsy) have approximately the same AUCs [0.65 (95%
CI 0.55–0.74) and 0.64 (95% CI 0.55–0.73), respectively].
For the DIPpsy the MIC-Pdeterioration (2.88) exceeds the
SRCgroup (2.80), but for the FIMcf the MIC-Pdeterioration
(1.47) is smaller than the SRCgroup (1.66). Of the
outcome measures related to social functioning, the RAP
sub-scale occupation (RAPocc) has the highest AUC
[0.73 (95% CI 0.64–0.81)] and an MIC-Pdeterioration
(7.74) exceeding the SRCgroup (4.24).
Table 5 shows the results for deterioration from the
clinician’s perspective. Because information from the EDSS
is used to obtain the external criterion, results for the EDSS
cannot be calculated. The two disease-specific outcome
Table 4 AUC, MIC-P and SRC for deterioration using the patient’s perspective as external criterion
Outcome measure AUC MICdeterioration SRCindividual SRCgroup Sample size*
AUC 95% CI
Disease-specific
EDSS 0.70 0.62–0.79 1.50 (ns) 16.04 3.15 467
MSFC** 0.62 0.53–0.72 0.05 (ns) 0.54 0.11 476
SaGAS** 0.65 0.56–0.75 0.05 (ns) 0.25 0.05 102
Physical functioning
Mobility
DIPmob 0.73 0.65–0.82 4.25 8.99 1.80 18
RAPmob 0.66 0.57–0.76 3.42 19.88 3.90 138
RMI 0.67 0.58–0.76 0.88 (ns) 5.91 1.16 184
SF36pf 0.75 0.67–0.84 8.58 21.91 4.38 27
TWT** 0.65 0.56–0.74 1.15 (ns) 2.56 0.50 20
Self-care
DIPself 0.70 0.62–0.79 2.11 9.54 1.91 83
FIMmf 0.68 0.59–0.76 1.45 5.74 1.13 64
RAPself 0.65 0.56–0.74 2.41 11.96 2.35 101
Upper limb function
ARAT 0.53 0.43–0.63 0.06 (ns) 1.61 0.32 2939
NHPT** 0.59 0.49–0.69 0.30 (ns) 2.82 0.55 361
Mental health
Cognitive function
FIMcf 0.65 0.55–0.74 1.47 8.47 1.66 136
PASAT3 0.50 0.40–0.60 2.56 19.62 4.18 240
Emotional well-being
DIPpsy 0.64 0.55–0.73 2.88 14.01 2.80 97
SF36mh 0.56 0.46–0.66 4.45 28.13 5.63 163
Social functioning
DIPsoc 0.68 0.59–0.77 2.84 8.08 1.62 33
RAPocc 0.73 0.64–0.81 7.74 21.63 4.24 32
SF36re 0.50 0.40–0.59 8.13 67.26 13.45 279
SF36rp 0.60 0.51–0.69 21.69 92.24 18.45 74
SF36sf 0.68 0.59–0.77 11.15 41.17 8.23 56
General health
SF36gh 0.66 0.57–0.75 9.86 26.61 5.32 30
AUC = area under the ROC curve at 3 years after baseline with 95% CIs; MICdeterioration = minimally important change; SRCindividual = smallest
real change at individual level; SRCgroup = smallest real change at group level, based on 26 stable patients at 6 months; ns = not significantly
different from 0.
*Patients per group, calculation based on a significance level of 0.05 and a power of 0.8.
**MSFC, SaGAS, NHPT and TWT data not transformed into a 0–100 point scale.
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measures have a very similar AUC [0.72 (95% CI 0.63–0.81)
for the SaGAS and 0.71 (95% CI 0.62–0.80) for the MSFC],
and for both the MIC-Cdeterioration was small and did not
significantly differ from zero. Of the outcome measures
related to physical functioning, SF36pf has the highest AUC
[0.72 (95% CI 0.63–0.80)] and an MIC-Cdeterioration (8.52)
that amply exceeds the SRCgroup (2.81). Of the outcome
measures related to mental health, the DIPpsy and the
PASAT3 (test 3-second version) have an AUC of 0.60 (95%
CI = 0.50–0.70 and 0.50–0.69, respectively). For both
outcome measures the MIC-Cdeterioration is small and does
not significantly differ from zero. Of the outcome measures
related to social functioning, the RAPocc has the highest
AUC [0.69 (95% CI 0.61–0.78)] and an MIC-Cdeterioration
(8.40) that amply exceeds the SRCgroup (2.69).
Regardless of the domain of the outcome measures, the
five most responsive (AUC) outcome measures to detect
deterioration from the patient’s perspective are the SF36pf
[0.75 (0.67–0.84)], the DIP sub-scale mobility [DIPmob;
0.73 (0.65–0.82)], the RAPocc [0.73 (0.64–0.81)], the DIP
sub-scale self-care [DIPself; 0.70 (0.62–0.79)] and the EDSS
[0.70 (0.62–0.79)]. Of these, only the EDSS does not fulfil
the criterion MIC-Pdeterioration > SRCgroup. The five most
responsive outcome measures to detect deterioration (AUC)
from the clinician’s perspective are the SaGAS [0.72 (0.63–
0.81)], the SF36pf [0.72 (0.63–0.80)], the MSFC [0.71 (0.62–
0.80)], the RAPocc [0.69 (0.61–0.78)] and the TWT [0.69
(0.59–0.78)]. Of these, only the SF36pf and the RAPocc have
an MIC-Cdeterioration > SRCgroup.
The results for improvement are less clear, because of the
small percentage of patients in the slightly improved groups
(data not shown). The MIC was either very small or did not
significantly differ from zero. Therefore, it was not possible
to compare the results with the SRC. Consequently, we can
Table 5 AUC, MIC-C, and SRC for deterioration using the clinician’s perspective as external criterion
Outcome measure AUC MICdeterioration SRCindividual SRCgroup Sample size*
AUC 95% CI
Disease-specific
EDSS
MSFC** 0.71 0.62–0.80 0.08 (ns) 0.72 0.08 331
SaGAS** 0.72 0.63–0.81 0.06 (ns) 0.44 0.04 220
Physical functioning
Mobility
DIPmob 0.66 0.57–0.75 2.56 10.52 1.06 69
RAPmob 0.67 0.58–0.76 5.62 16.26 1.63 34
RMI 0.65 0.56–0.75 1.30 7.53 0.75 137
SF36pf 0.72 0.63–0.80 8.52 27.99 2.81 44
TWT** 0.69 0.59–0.78 0.34 (ns) 3.03 0.30 324
Self care
DIPself 0.65 0.55–0.74 2.16 8.70 0.87 66
FIMmf 0.68 0.59–0.77 1.70 6.43 0.64 58
RAPself 0.62 0.52–0.72 1.33 (ns) 14.79 1.48 505
Upper limb function
ARAT 0.55 0.45–0.65 0.14 (ns) 5.27 0.53 5784
NHPT** 0.67 0.58–0.76 0.51 (ns) 5.32 0.53 444
Mental health
Cognitive function
FIMcf 0.54 0.44–0.64 1.41 6.26 0.63 80
PASAT3 0.60 0.50–0.69 0.77 (ns) 26.45 2.77 4816
Emotional well-being
DIPpsy 0.60 0.50–0.70 1.11 (ns) 16.68 1.68 922
SF36mh 0.55 0.45–0.65 2.48 (ns) 28.44 2.86 537
Social functioning
DIPsoc 0.64 0.55–0.74 2.16 10.27 1.03 92
RAPocc 0.69 0.61–0.78 8.40 26.89 2.69 42
SF36re 0.53 0.43–0.63 4.79 (ns) 74.24 7.46 980
SF36rp 0.61 0.51–0.71 12.29 89.05 8.95 214
SF36sf 0.60 0.51–0.70 5.04 40.71 4.09 266
General health
SF36gh 0.51 0.42–0.61 3.15 (ns) 30.71 3.09 388
AUC = area under the ROC curve at 3 years after baseline with 95% CIs; MICdeterioration = minimally clinically important change;
SRCindividual = smallest real change at individual level; SRCgroup = smallest real change at group level, based on 100 stable patients at 6 months;
ns = not significantly different from 0.
*Patients per group, calculation based on a significance level of 0.05 and a power of 0.8.
**MSFC, SaGAS, NHPT and TWT data not transformed into a 0–100 point scale.
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only look at the relative responsiveness by comparing the
AUCs. From the patient’s perspective, the highest AUCs
were found for the EDSS [0.78 (95% CI 0.70–0.87)], the
DIPmob [0.73 (95% CI 0.64–0.85)], the FIM sub-scale
motor function [FIMmf; 0.71 (0.63–0.80)], the SF36pf [0.71
(95% CI 0.62–0.80)] and the RAPocc [0.71 (95% CI 0.62–
0.82)]. From the clinician’s perspective, the highest AUCs
were found for the RAPocc [0.79 (95% CI 0.63–0.95)], the
SF36pf [0.77 (95% CI 0.64–0.90)], the FIMmf [0.74 (95% CI
0.62–0.86)], the FIMcf [0.74 (95% CI 0.59–0.90)] and the
RAPmob [0.72 (95% CI 0.58–0.87)]. Irrespective of the
external criterion that is applied, the most responsive
outcome measures to detect improvement are the FIMmf,
the SF36pf, the RAPocc and the EDSS. However, the
criterion MIC > SRC could not be evaluated for any of the
measures.
Discussion
In the early stages of multiple sclerosis, the two most useful
evaluative outcome measures to detect deterioration, and that
perform well irrespective of the external criterion that
is applied, are the SF36pf for the physical functioning domain
(mobility), and the RAPocc for the social functioning domain.
Both measures have an MIC > SRCgroup, which makes them
suitable for application in clinical research. However, none of
the outcome measures that we studied had an MIC >
SRCindividual, which means that the reliability demands that
warrant application at individual patient level are not met.
The selection of an outcome measure is not only guided
by its responsiveness. It is also important to select an
outcome measure that really measures the phenomena of
interest. Therefore, we categorized the outcome measures
that we have studied into five domains and five sub-
domains, which should guide their selection. Before the
final selection of an outcome measure, one should study
the content of an outcome measure to make sure it measures
the variable one is interested in. The measures that perform
best in the other domains are the DIPpsy (mental health
domain, emotional well-being) and the SF36gh (general
health domain), but none of the disease-specific outcome
measures fulfilled our selection criteria.
We were looking for an outcome measure with a per-
formance that did not depend on the required perspective.
Finding such an outcome measure would increase our
confidence in this measure, because it would imply that the
results obtained with this measure have the same meaning
for both the clinician and the patient. However, it might be
very legitimate to emphasize one or both perspectives
depending on the research aim. For more basic research
purposes reliance on examiner-driven outcomes might be
fully acceptable. But for more clinically oriented research
questions, i.e. studies that are interested in the effects on
patients, such as clinical trials, reliance on examiner-driven
assessments only is not sufficient. In these studies one
should also include patient-driven outcome measures,
because that is the only way to show benefit for patients.
For the evaluation of this kind of clinically oriented research
it would be very valuable to have a (primary) outcome
measure available which evaluative ability is independent of
the chosen perspective (patient versus examiner), because
only then the MIC is the same for the patient and the
examiner, which facilitates the interpretation of this
research.
An important strength of this study is the simultaneous
evaluation of several outcome measures that are frequently
used in multiple sclerosis research. Scores were collected for
23 (sub-scales of) outcome measures in the same patients
and in the same way. This enables a direct comparison of the
outcome measures, and facilitates interpretation of the
results. Information about the responsiveness of outcome
measures is often derived from several studies with
different designs, different populations, different anchors,
and different outcome measures. This hampers the selection
of the most responsive outcome measure, because no direct
comparison can be made.
The relative responsiveness is quite independent of the
particular approach to the evaluation of responsiveness
(Terwee et al., 2003). We chose the approach presented in
this article for two reasons. First of all, we aimed to identify
the most responsive outcome measures by comparing the
outcome measures on the basis of the AUC (relative
responsiveness). Second, we tried to obtain data that would
facilitate the interpretation of score changes in future
studies. The interpretation depends on two aspects of the
score change: (i) what is a minimally important change, and
(ii) is the instrument capable of measuring this change? We
have used the MIC as a measure of minimally important
change, and the SRC to estimate the ability of a measure to
detect this change. From our results we conclude that our
strategy worked well for the analysis of changes in the
direction of deterioration, because we were able to clearly
show the relative responsiveness, and provide clear data that
facilitate the interpretation of score changes. However, the
results with regard to changes in the direction of
improvement are inconclusive, due to the small number of
patients in this category.
Another aspect of this study that deserves some attention
is the analysis of repeated measures. We made optimal use
of the longitudinal data by applying longitudinal data-
analysis techniques, which reduces the standard error of our
estimates. Moreover, we constructed a regression model
that enabled us to estimate the MIC for deterioration and
improvement in one model. The possibility of this study to
show improvement is limited by its design, because
recruiting recently diagnosed patients, who are only mildly
disabled, implies a limitation in the possibility to improve.
Therefore, our results for improvement are not as clear as
those for deterioration. However, despite this limitation,
the study does provide some preliminary evidence that the
MICdeterioration and the MICimprovement are not necessarily
equal (Cella et al., 2002b).
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A well-known problem in studies of anchor-based res-
ponsiveness is the choice of the external criterion to define
change (Cella et al., 2002a). Norman et al. (1997) compared
two methods to assess responsiveness with each other: (i) an
effective therapy as construct for change, and (ii) a
retrospective method to assess change using a GRS. In this
direct comparison the GRS performs worse than the effective
therapy as external criterion. The problem with the
generalization of these results is that there is often not an
effective therapy available. Particularly in longitudinal
cohort studies, such as ours, we cannot rely on an effective
therapy. There are ways to use effective therapy as construct
for change in multiple sclerosis by applying outcome
measures in patients that were treated for a relapse with
corticosteroids. A major problem in these studies is that one
is looking at improvements. It is absolutely not certain that
these results can subsequently be used in studies that look at
deterioration.
Because a gold standard for change is lacking, we had to
rely on other methods to define change. We decided not to
rely on one method, because the chosen method to define
change influences the results of the analyses. Furthermore,
we carefully sought for sensible external criteria. Roughly
speaking, there are three constructs for the evaluation of
change in multiple sclerosis: data obtained from repeated
MRI studies, the EDSS as the most frequently used clinical
outcome measure, and a GRS which emphasizes the
perspective of the patient. Our main focus in this study
was on disability and quality of life. Therefore, using MRI
data as a construct for change is not appealing, since it only
offers information at the level of pathological changes,
which are only remotely related to disability and even less
related to quality of life. The EDSS has limitations with
regard to its validity and reliability, which might make it
relatively unsuitable as an external criterion for change.
However, despite this criticism, it is a scale that is very well
known among clinicians. It is, in fact, so well-known that a
description of a study population is not complete without
EDSS data. Therefore, we used the EDSS to determine
important change from a clinician’s point of view. Because
the first question of a clinician during a visit often is a global
rating: ‘How are you doing since the last visit’, and because
a stronger external criterion is lacking, we used a GRS
to emphasize the perspective of the patient. Because all
outcomes were compared with these two sensible external
criteria, we made insightful what the effect of the external
criteria is.
A global rating requires that patients are able to mentally
subtract a previous situation from the present situation
(Liang, 1995; Stratford et al., 1996). Criticism about the use
of a GRS concerns the fact that this rating has often been
found to show stronger associations with the present
situation than with the previous situation (Guyatt et al.,
2002). In an attempt to overcome this problem, we coupled
the previous situation to an important life-event for
the patient. In this way, we tried to facilitate the mental
subtraction, and hoped for more equal associations of
the GRS with the previous and the present situation.
We considered the time of diagnosis as an important life-
event. Because in our study patients were not diagnosed
until some time after their exacerbation and because the
mean time between diagnosis and first measurement is
relatively short (3.5 months), we decided that it was valid to
use it as reference point. Our strategy was partly successful.
The mean correlation coefficient between the GRS at 3 years
and the outcome measures at baseline was 0.26 (range 0.15–
0.43), at 6 months it was 0.30 (range 0.14–0.44), at 1 year it
was 0.33 (range 0.14–0.49), at 2 years it was 0.37 (range 0.09–
0.56), and at 3 years it was 0.40 (range 0.14–0.59).
Another point of discussion about the use of the GRS as
external criterion is the choice of the cut-off point used for
the calculation of the MIC. We decided to use the category
‘slightly deteriorated’ or ‘slightly improved’ as indicator of
minimally important change. In our opinion, the next
category (‘much deteriorated’ or ‘much improved’) is, at
least semantically, not equivalent to minimally important
change. Others have argued that using ‘much deteriorated’
or ‘much improved’ is more appropriate than ‘slightly
deteriorated’ or ‘slightly improved’, because the latter two
categories are often used by patients who are reluctant to
classify themselves as stable, while their situation would
justify this classification (Ostelo and De Vet, 2005). We
performed a sensitivity analysis (data not shown), with the
category ‘much deteriorated’ as cut-off, and compared the
MIC-P and the MIC-P estimates obtained in this sensitivity
analysis (MIC-Psens) with the MIC-C. For 17 outcome
measures the MIC-P was closer to the MIC-C than the
MIC-Psens, indicating that there is a greater correspondence
between the MIC-P and the MIC-C than between the
MIC-Psens and the MIC-C, which supports the use of the
category ‘slightly deteriorated’ as cut-off in this sample. In
future studies it might be useful to add extra categories to
the GRS between ‘slightly’ and ‘much’, for example by using
‘deteriorated’ and ‘improved’ on their own, and to use
these categories to determine the MIC. This might lessen the
(semantic) gap between ‘slightly’ and ‘much’, and might aid
patients who are reluctant to use the category ‘stable’,
without influencing the estimation of the MIC.
Recently, Solari et al. (2005) studied the practice effects of
the MSFC and suggested that, to improve efficiency, one
prebaseline administration of TWT, three of PASAT and
four of NHPT are needed. Their study consisted of repeated
administrations of the tests in 1 day. What their results
mean for repeated MSFC measurements with intervals of
6 months or longer, such as our study, is not immediately
clear. Will you never lose your ability to perform the PASAT
or NHPT once you have mastered it, or do you again need
some prebaseline administrations after you have not been
performing the PASAT or NHPT for some time? For the
components of the MSFC and the SaGAS we used the same
test protocol at each measurement. The NHPT and the TWT
were conducted twice. For the TWT this is sufficient, for the
2656 Brain (2006), 129, 2648–2659 V. de Groot et al.
 at Vrije Universiteit - Library on July 19, 2011
brain.oxfordjournals.org
D
ow
nloaded from
 
NHPT two additional administrations would have been
better. The PASAT was always administered once, but in any
case after at least one practice trial, as described in the MSFC
manual. Although the interval between subsequent measure-
ments was at least 6 months, we cannot rule out a practice
effect. Ignoring a possibly present practice effect will lead to
inflated measures of responsiveness in the direction of
deterioration for the NHPT and PASAT, because the
measured change in cognitive or upper limb function is
smaller than the real change. The opposite would occur for
the measures of responsiveness in the direction of
improvement, because the measured improvement in
cognitive function is larger than the real improvement.
Although we were able to identify the most responsive
outcome measures and to show, for several of these out-
come measures, that the signal (MIC) exceeds the noise
(SRCgroup), it should be noted that our results are not
automatically applicable to all patients with multiple
sclerosis. In general, our population was only mildly
disabled, had a disease duration of just over 3 years at the
end of the study, and was treated with disease modifying
treatment if indicated (44 patients were on disease
modifying treatment at the end of the study). Because this
treatment will influence the outcomes and the external
criteria in the same direction, it will probably not sig-
nificantly alter our results. The results of this study can
therefore be used in early intervention studies. With the
positive effects of disease modifying treatments, patients
will be mildly disabled for a longer period. Future trials will
have to compare newly developed treatments with the
current disease modifying treatments. Showing differences
in effectiveness in these studies will increasingly suffer
from power problems. In comparative studies an outcome
measure should be able to show differences between
longitudinal changes of two (or more) groups (arms of a
trial), which is probably more difficult than showing changes
within one group only. In our opinion this is a requirement
that can only be fulfilled when an outcome measure is
already capable of detecting longitudinal changes. Our
results clearly show that some of the outcome measures that
we have studied, and that are not regularly used in trials, are
more suitable to evaluate changes than others. In the early
stages of multiple sclerosis a reduction of the walking
distance is more often a problem than a reduction in
walking speed. The SF36pf probably performs well because
it also contains items about walking distance, whereas the
regularly used TWT only measures walking speed. The
RAPocc and, to a lesser extent, the DIPsoc, probably
perform well because they measure social functioning.
Although social functioning is seriously affected in the early
stage of multiple sclerosis, it is not part of the measures that
are regularly used in trials. Future responsiveness studies
should focus on more severely disabled populations and
populations with a longer duration of the disease.
None of the outcome measures used in this study could
detect important change in individual patients. Outcome
measures that might be useful should have a relatively low
SRCindividual. This point has already been acknowledged in
relation to the MSFC. Several authors have stated that
a change of 20% for the components of the MSFC is
required to exceed measurement error (Kaufman et al., 2000;
Schwid et al., 2002) and that changes for the MSFC and
SaGAS should be >0.5 (Hoogervorst et al., 2004; Vaney et al.,
2004). Depending on the external criterion used, we found
that in our sample a change of 2.6–3.0 s (40% of baseline)
for the TWT and 2.8–5.3 s (13% of baseline) for the NHPT
is required to exceed measurement error. In our sample,
changes in MSFC and SaGAS should exceed 0.54–0.72 and
0.25–0.44, respectively, in order to indicate significant
change. However, MSFC scores should be interpreted with
caution, because it is not evident from the total score which
component contributes most to the total score. The
differences between results reported in the literature
(Kaufman et al., 2000; Schwid et al., 2002; Hoogervorst
et al., 2004; Vaney et al., 2004) and our results might be
explained by our study design. We recruited recently
diagnosed patients, whereas in the other studies
the patients had the disease for various lengths of time.
Furthermore, we used a fixed interval of 6 months between
visits to identify the stable patients, whereas the other
studies used a 5-day or a variable interval. The design of the
present study matches usual patient care, which increases
the validity of our results, but, unfortunately, leads to the
conclusion that the outcome measures in this study are not
suitable for detecting change within a few years in
individual, recently diagnosed, patients.
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